Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedA newer revision number (v3.6.2) is now shown, indicating a behind-the-scenes update to the site. This update does not modify the study information displayed on the page.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedNew navigation/help sections such as How to Read a Study Record, Common Questions, and How to Join a Study were added, and a version update indicates v3.6.0. The investigator name presentation and related metadata were adjusted (e.g., William Gradishar entry and related labels).SummaryDifference1%

- Check24 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a minor page update or bug fix. It does not appear to modify the study details, eligibility criteria, or results on the page.SummaryDifference0.1%

- Check46 days agoChange DetectedPage revision updated from v3.5.3 to v3.5.4. This update is a metadata/version bump and does not change the study content or user-facing information.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page’s footer revision/version has been updated from v3.5.2 to v3.5.3, reflecting a site interface update rather than a change to the clinical trial record.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.